Pacira BioSciences (PCRX) Competitors $19.72 -0.11 (-0.55%) (As of 10:36 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PCRX vs. PRGO, SUPN, OMER, NKTR, ASMB, CPIX, LLY, JNJ, ABBV, and MRKShould you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co., Inc. (MRK). These companies are all part of the "pharmaceuticals" industry. Pacira BioSciences vs. Perrigo Supernus Pharmaceuticals Omeros Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Perrigo (NYSE:PRGO) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability, institutional ownership and community ranking. Does the media favor PRGO or PCRX? In the previous week, Pacira BioSciences had 11 more articles in the media than Perrigo. MarketBeat recorded 18 mentions for Pacira BioSciences and 7 mentions for Perrigo. Perrigo's average media sentiment score of 0.99 beat Pacira BioSciences' score of 0.38 indicating that Perrigo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in PRGO or PCRX? 95.9% of Perrigo shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 0.7% of Perrigo shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor PRGO or PCRX? Pacira BioSciences received 54 more outperform votes than Perrigo when rated by MarketBeat users. Likewise, 71.59% of users gave Pacira BioSciences an outperform vote while only 66.67% of users gave Perrigo an outperform vote. CompanyUnderperformOutperformPerrigoOutperform Votes77066.67% Underperform Votes38533.33% Pacira BioSciencesOutperform Votes82471.59% Underperform Votes32728.41% Which has better earnings & valuation, PRGO or PCRX? Pacira BioSciences has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerrigo$4.39B0.82-$12.70M-$1.17-22.58Pacira BioSciences$694.96M1.32$41.96M-$2.03-9.77 Do analysts rate PRGO or PCRX? Perrigo presently has a consensus price target of $37.00, indicating a potential upside of 40.05%. Pacira BioSciences has a consensus price target of $23.50, indicating a potential upside of 18.51%. Given Perrigo's stronger consensus rating and higher probable upside, equities analysts plainly believe Perrigo is more favorable than Pacira BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perrigo 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Pacira BioSciences 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has more risk and volatility, PRGO or PCRX? Perrigo has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Is PRGO or PCRX more profitable? Perrigo has a net margin of -3.64% compared to Pacira BioSciences' net margin of -13.07%. Pacira BioSciences' return on equity of 13.42% beat Perrigo's return on equity.Company Net Margins Return on Equity Return on Assets Perrigo-3.64% 7.38% 3.18% Pacira BioSciences -13.07%13.42%7.19% SummaryPacira BioSciences beats Perrigo on 12 of the 18 factors compared between the two stocks. Ad Diversified Trading InstituteGenesis leading the smart algo revolution?I’m revealing an exciting breakthrough that can help trade the markets unlike anything you’ve ever seen before… Because with my BRAND NEW smart algo you’ll always have a constant stream of alerts firing off in your back pocket to choose from. Here’s why: It does all the heavy lifting for you… automatically. Stock Ticker, Entry Price, Profit Target, Stop Loss, and even an Individual Chart!You’ll want to see what I’ve put on this page right here Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCRX vs. The Competition Export to ExcelMetricPacira BioSciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$910.53M$6.84B$5.14B$9.30BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-9.7110.77135.3017.49Price / Sales1.31284.121,186.56136.36Price / Cash5.0256.6540.4237.95Price / Book1.055.374.874.92Net Income$41.96M$151.75M$118.61M$225.42M7 Day Performance-3.00%-4.72%15.32%-1.20%1 Month Performance18.51%2.09%15.26%7.09%1 Year Performance-36.08%16.12%34.42%22.83% Pacira BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCRXPacira BioSciences3.8508 of 5 stars$19.72-0.6%$23.50+19.2%-36.6%$910.53M$694.96M-9.71720Analyst RevisionGap DownPRGOPerrigo4.9785 of 5 stars$27.01-1.6%$37.00+37.0%-9.7%$3.68B$4.66B-23.469,140SUPNSupernus Pharmaceuticals2.4962 of 5 stars$36.62+1.2%$36.00-1.7%+32.9%$2.02B$651.97M33.91580OMEROmeros3.5957 of 5 stars$7.79+2.1%$9.00+15.5%+177.5%$451.43MN/A0.00198Positive NewsNKTRNektar Therapeutics4.4834 of 5 stars$1.03+2.0%$4.10+298.1%+117.7%$189.99M$93.14M-1.20220ASMBAssembly Biosciences4.1166 of 5 stars$15.50+0.8%$35.00+125.8%+58.1%$98.52M$28.33M0.00100Gap UpCPIXCumberland Pharmaceuticals0.4576 of 5 stars$2.17-8.8%N/A+19.8%$30.47M$36.79M-2.8380Gap UpLLYEli Lilly and Company4.9951 of 5 stars$779.34-1.2%$1,002.22+28.6%+36.1%$739.84B$40.86B85.4843,000Buyback AnnouncementJNJJohnson & Johnson4.9202 of 5 stars$145.04-1.1%$174.73+20.5%-5.7%$349.20B$87.70B21.22131,900Positive NewsABBVAbbVie4.9486 of 5 stars$172.71-0.4%$203.65+17.9%+13.9%$305.20B$55.53B60.2350,000Analyst ForecastMRKMerck & Co., Inc.4.9924 of 5 stars$100.98-0.2%$129.20+27.9%-4.8%$255.44B$60.12B21.3172,000 Related Companies and Tools Related Companies Perrigo Competitors Supernus Pharmaceuticals Competitors Omeros Competitors Nektar Therapeutics Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors AbbVie Competitors Merck & Co., Inc. Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PCRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
